Literature DB >> 18041871

The state of insomnia and emerging trends.

Thomas Roth1, Meg Franklin, Thomas J Bramley.   

Abstract

Recent research into the pathophysiology of insomnia has brought a shift in the approach to treatment. Insomnia rarely occurs in isolation and is typically comorbid with other conditions. Rather than simply treating the primary disorder, whereby symptoms of insomnia may go unaddressed, now there is a push to acknowledge the existence of chronic insomnia as a disorder that itself merits treatment. This recognition is due to the identification of pathophysiologic changes and associated morbidity, which can be substantial. Insomnia patients have increased risk for psychiatric disorders, especially depression, anxiety, decreased quality of life, increased healthcare utilization and costs, drug/alcohol abuse, decreased occupational performance, and increased falls/accidents. Current management patterns explore non-nightly or discontinuous hypnotic treatment - non-nightly flexible, non-nightly semiflexible, non-nightly fixed, and flexible timing - which deviates from past trends of continuous dosing with hypnotics. These trends reflect a change from considering insomnia a symptom to treating insomnia as a disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18041871

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  10 in total

1.  Problems sleeping with prostate cancer: exploring possible risk factors for sleep disturbance in a population-based sample of survivors.

Authors:  Rebecca Maguire; Frances J Drummond; Paul Hanly; Anna Gavin; Linda Sharp
Journal:  Support Care Cancer       Date:  2019-01-09       Impact factor: 3.603

2.  Evaluation of the PHQ-9 Item 3 as a screen for sleep disturbance in primary care.

Authors:  Kristin L MacGregor; Jennifer S Funderburk; Wilfred Pigeon; Stephen A Maisto
Journal:  J Gen Intern Med       Date:  2011-09-24       Impact factor: 5.128

3.  Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study.

Authors:  Michael Perlis; Michael Grandner; Jarcy Zee; Erin Bremer; Julia Whinnery; Holly Barilla; Priscilla Andalia; Phil Gehrman; Knashawn Morales; Michael Thase; Richard Bootzin; Robert Ader
Journal:  Sleep Med       Date:  2015-07-07       Impact factor: 3.492

4.  Correcting delayed circadian phase with bright light therapy predicts improvement in ADHD symptoms: A pilot study.

Authors:  Rachel E Fargason; Aaron D Fobian; Lauren M Hablitz; Jodi R Paul; Brittny A White; Karen L Cropsey; Karen L Gamble
Journal:  J Psychiatr Res       Date:  2017-03-06       Impact factor: 4.791

5.  Effects of different doses of triazolam in the middle-of-the-night insomnia: a double-blind, randomized, parallel group study.

Authors:  Luigi Ferini Strambi; Sara Marelli; Marco Zucconi; Andrea Galbiati; Giovanni Biggio
Journal:  J Neurol       Date:  2017-06-05       Impact factor: 4.849

6.  The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain.

Authors:  Carla R Jungquist; Chris O'Brien; Sara Matteson-Rusby; Michael T Smith; Wilfred R Pigeon; Yinglin Xia; Naiji Lu; Michael L Perlis
Journal:  Sleep Med       Date:  2010-02-04       Impact factor: 3.492

Review 7.  Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923

8.  Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial.

Authors:  Charles M Morin; Annie Vallières; Bernard Guay; Hans Ivers; Josée Savard; Chantal Mérette; Célyne Bastien; Lucie Baillargeon
Journal:  JAMA       Date:  2009-05-20       Impact factor: 56.272

Review 9.  Ramelteon: a review of its use in insomnia.

Authors:  Dene Simpson; Monique P Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Clinical management of insomnia with brief behavioral treatment (BBTI).

Authors:  Wendy M Troxel; Anne Germain; Daniel J Buysse
Journal:  Behav Sleep Med       Date:  2012-10       Impact factor: 2.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.